IL10 and neoplasm: The hypoxia of tumor microenvironment suppresses metabolic activity and viability of DCs (Taylor and Scholz 2022), or tumor cells reduce the immune activity of dendritic cells directly by secreting interleukin-6 (IL-6), interleukin-10 (IL-10), and transforming growth factor-β (TGF-β) (Wculek et al. 2020).